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Abstract: Selectively fluorinated compounds are found frequently in 
pharmaceutical and agrochemical products where currently 25-30% 
of optimized compounds emerge from development containing at 
least one fluorine atom. There are many methods for site specific 
introduction of fluorine, but all are chemical and they often use 
environmentally challenging reagents. Biochemical processes for C-
F bond formation are attractive but they are extremely rare. In this 
work the fluorinase enzyme, originally identified from the 
actinomycete bacterium S. cattleya, is engineered into E. coli in a 
manner where the organism is able to produce 5’-
fluorodeoxyadenosine (5’-FDA) from S-adenosyl-L-methionine (SAM) 
and fluoride in live E. coli cells. Success required the introduction of a 
SAM transporter and deletion of the endogenous fluoride efflux 
capacity, in order to generate an E. coli host which has potential for 
future engineering of more elaborate fluorometabolites.  
Fluorine is the most abundant halogen found in the Earth’s crust, 
but despite its geological dominance among the halogens, the 
concentration of soluble fluoride in the oceans and surface water 
is very low and its bioavailability is restricted.[1] Additionally, a 
fluoride ion is not readily oxidised like the other halogens e.g. by 
haloperoxidases. Moreover, it is the most strongly hydrated halide, 
thus catalytic processes need to overcome considerable kinetic 
barriers to achieve reactivity. Therefore, the occurrence of 
fluorometabolites is extremely rare and a biotechnology 
associated with organofluorine production from fluoride is 
essentially absent.[2] This can be contrasted with the very large 
anthropogenic focus on fluorine for the fine tuning of properties 
associated with the industrial development of performance 
chemicals. As a result, a rich and wide-ranging chemistry has 
emerged, associated with the chemical incorporation of fluorine in 
performance organic molecules ranging from materials to 
bioactives.[3] 
The first fluorometabolite to be identified in nature (1944)[4] 
was fluoroacetate (FAc), an acute toxin which has subsequently 
been shown to be produced by a range of tropical and subtropical 
plants.[5, 6] Its origin in plants remains unknown, however the 
biosynthesis of FAc and co-produced 4-fluorothreonine (4-FT) in 
bacteria has been elucidated in Streptomyces cattleya.[7, 8] This 
actinomycete contains six genes encoding enzymes which 
process inorganic fluoride and SAM to FAc and 4-FT (Scheme 1). 
The pathway itself has been reconstituted in vitro by combining 
the over-produced enzymes into an NMR tube.[9] The first 
Scheme 1. The 4-FT - FAc pathway from S. cattleya. The reaction catalyzed by 
5’-FDA synthase (fluorinase) generates 5’-FDA from SAM.[10, 11] This is the first 
step in fluorometabolite biosynthesis, a rare process which has been identified 
only in a small number of actinomycete bacteria.[12] 
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committed enzyme in the 4-FT and FAc pathway is the fluorinase, 
which catalyzes C-F bond formation during the conversion of SAM 
to 5’-fluoro-5’-deoxyadenosine (5’-FDA)[10, 11] and this became the 
target enzyme for in vivo expression in E. coli as illustrated in 
Scheme 1. 
Subsequent to the original fluorinase isolation from S. 
cattleya, four more variants have been functionally demonstrated 
after their identification by genome mining. All genes exhibited 
high sequence homology (80%-87%) with the original gene from 
S. cattleya and all corresponding enzymes had a similar catalytic 
efficiency.[12] These included a fluorinase from the marine 
bacterium Streptomyces xinghaiensis, which was able to produce 
FAc in a sea salt medium.[13, 14] As more bacterial genome 
sequences are deposited in public databases, it seems likely that 
more fluorinases will emerge. A current BLAST search identified 
two more open reading frames (ORFs) which are predicted to 
encode for fluorinases with a sequence identity of ~80%, (from 
Actinopolyspora mzabensis and Amycolatopsis sp. CA-128772 
genomes). 
In this work, a rational strategy for developing an 
engineering platform for in vivo fluorination based on E. coli 
BL21(DE3) was explored, with a specific focus to establish 5’-FDA 
production. This particular strain was used as it has already been 
utilized in fluorinase over-expression. A particular concern was 
the well-described ability of fluoride to inhibit growth in bacteria.[15] 
Fluoride enters the cell by passive diffusion across the membrane 
as neutral hydrogen fluoride (HF), where it then dissociates to 
fluoride ions.[16] It has been reported that the presence of cellular 
fluoride in the millimolar range inhibits some key enzymes 
involved in glucose metabolism, such as enolase[17] and 
pyrophosphatase.[18] Several studies have revealed a wide variety 
of proteins that play a role in managing high fluoride ion 
concentrations in bacterial or eukaryotic hosts.[15, 19-21] These are 
transmembrane channels that serve as pumps expelling fluoride 
which has entered passively as HF. E. coli employs such a 
channel protein termed CrcB which it uses to achieve fluoride 
resistance.[15] Mutant E. coli strains with the crcB gene deleted, 
exhibit a 200-fold greater sensitivity to extracellular fluoride 
relative to wild type. The mechanism of action of CrcB was 
evidenced by the fact that the intracellular concentration of 
fluoride in a ΔcrcB strain remained at much higher levels 
compared to the wild type, under the same extracellular fluoride 
concentration.[15] Additionally, passive HF trans-membrane 
ingress is a pH-dependent process.[16] A study in S. cattleya has 
indicated that fluoride uptake - and therefore intracellular 
availability - directly influences in vivo fluorometabolite production 
by triggering the upregulation of key biosynthetic enzymes.[22] 
This has been attributed to a fluoride uptake mechanism in S. 
cattleya, although such a mechanism remains to be confirmed. 
Alternatively, the absence of a fluoride efflux channel in S. 
cattleya would be sufficient to allow fluoride to accumulate 
passively, consistent with the pH-dependence of fluoride uptake 
and the growth retardation of S. cattleya above 2 mM added 
fluoride [23]. In other fluoride channel-expressing bacteria, such as 
E. coli, millimolar fluoride supplied in the growth medium has little 
effect on growth. In this context, deletion of the crcB gene was 
explored to raise intracellular fluoride concentrations, and counter 
the relatively poor affinity of fluoride ion for the fluorinase 
(millimolar level Km for fluoride). [11, 12] 
A second modification addressed deletion of the deoD gene 
encoding a purine nucleoside phosphorylase (PNP) in E. coli. This 
enzyme can cleave purine bases including adenosine from purine 
nucleosides to generate ribose-1-phosphate.[24, 25] A PNP in S. 
cattleya catalyzes the second step of the fluorometabolite 
pathway and converts 5’-FDA to yield 5-fluoro-5-deoxy-D-ribose 
1-phosphate (5-FDRP).[26] The logic behind deoD deletion was to 
remove this PNP activity and suppress any adventitious 5’-FDA 
degradation. Such a consideration was noted in a recent study 
exploring directed evolution of the fluorinase involving E. coli cell-
free extract incubations.[27] 
A third modification involved the expression of a gene 
encoding a transmembrane SAM transporter in order to increase 
the pool of intracellular SAM for the fluorinase reaction. SAM 
transporters are found in symbiotic organelles such as 
mitochondria[28, 29] and plastids.[30] Some intracellular parasites, 
including Rickettsia prowazekii RP076 and Chlamydia 
trachomatis contain SAM transporter genes. These have been 
expressed in otherwise non-viable E. coli strains, with the gene 
encoding for the SAM producing enzyme (metK) deleted. 
Expression of the transporter genes with external 
supplementation of SAM rescued growth in these strains.[31, 32] We 
chose the SAM transporter from R. prowazekii (hereafter denoted 
SAMT) because it is an energy-dependent channel protein 
transporting SAM only from the extracellular to the intracellular 
environment contrary to the Chlamydial transporter which 
exchanges SAM for S-adenosyl-L-homocysteine (SAH). 
Figure 1. Schematic of the variables in the engineered E.coli BL21(DE3) cells showing plasmids carrying the fluorinase (flA1) and SAM transporter (samT) genes, 
as well as the chromosomal knockouts of the fluoride ion channel (crcB) and purine nucleoside phosphorylase (deoD).  
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Moreover, optimal growth of the ΔmetK strain was observed with 
a much lower molarity of supplemented SAM in the growth 
medium. 
Figure 1 illustrates the key modifications of the engineered 
E. coli and Table S2 summarizes the engineered E. coli strains 
and comparative incubations carried out in order to identify the 
impact that each modification had on fluorometabolite production. 
The fluorinase gene was adopted from Streptomyces sp. MA37 
(flA1) which was characterized as the most efficient fluorinase 
based on enzyme kinetics [12] and was inserted in the expression 
plasmid after codon optimization for E. coli (gene sequence in SI). 
Both deletions were achieved by suicide plasmid integrations in 
the chromosome and homologous recombination as originally 
described.[33] Incubations were supplemented with 2 mM KF and 
500 μM SAM. For a more detailed description see Supporting 
Information.  
It is noteworthy that fluorinase over-expression in all tested 
strains seemed to stimulate growth to a higher bacterial mass 
during stationary phase. In order to further explore this effect, 
strains BL21(DE3) (no plasmids), MK007 (BL21(DE3) with 
negative control plasmid pET(-)) and MK004 (BL21(DE3) with 
fluorinase expression plasmid, pflA1) were grown in 96-well 
plates and their growth was monitored. Results are presented in 
Figure S9. Indeed, higher growth is observed in the BL21(DE3) 
strains expressing the fluorinase when compared to BL21(DE3) 
strains free of plasmids, negative control (MK007 – pET(-)) or 
basal expression (MK004 without IPTG). Generally, protein over-
expression will impede growth even in the case of over-production 
of an inert protein.[34] To explore if this effect was due to increased 
levels of intracellular protein accumulation due to over-expression, 
varying levels of induced expression of the fluorinase (IPTG 0.02 
mM to 0.08 mM) were included. The indifference of stationary OD 
levels between different expression levels confirms that the higher 
stationary optical density (OD) observed is not due to protein 
accumulation. The origin of this effect is unclear but it bodes well 
for future development as recombinant expression of 
heterologous proteins can often lead to genetic instability of the 
host, due to toxicity or added metabolic burden.[35] 
Initially, strains including either all modifications or all but 
PNP deletion (thought as most promising for achieving in vivo 
fluorination) were tested, specifically strains MK015 (ΔcrcB + 
pflA1 + psamT) and MK019 (ΔcrcBΔdeoD + pflA1 + psamT) with 
their negative control counterparts MK016 and MK020. Lysates 
and supernatants from two replicates were assayed by HPLC and 
also 19F-NMR, which directly reports fluorinated products. The 
lysates in both of fluorinase containing strains MK015 and MK019 
showed clear 19F-NMR signals associated with 5’-FDA as the only 
organo-fluorine product whereas the corresponding negative 
controls (MK016 and MK020) without the flA1 gene, did not.  
A series of experiments (see SI for details) explored 
incubations of engineered E. coli’s with and without samT 
expression and crcB gene active or deleted. Cell extracts were 
evaluated by 19F-NMR (Figure 2). No 5’-FDA was detected in 
MK004 and MK010, both of which express flA1 but not samT, with 
MK010 having an inactivated fluoride efflux channel. This is 
contrasted with 5‘-FDA production in MK015 (PNP intact) and 
MK019 (PNP inactive) both of which express samT but have their 
efflux channels inactivated. The stability of 5’-FDA in these strains 
suggests that it is not degraded in vivo by the PNP or other 
potential metabolizing enzymes such as adenosine deaminase as 
no additional fluorometabolites were identified by 19F-NMR. It 
should be noted that in cell-free extracts of S. cattleya 5’- FDA is 
metabolised to 5’-FDI by an endogenous deaminase, a process 
that does not occur in whole cell incubations, suggesting some 
level of compartmentalisation, which may be the case in E. Coli 
as well.[24] The necessity for both fluoride channel deletion and 
samT expression to achieve 5’-FDA production was recognised 
with strain MK008 (Figure S10). This strain which has an active 
fluoride efflux channel, as well as flA1 and samT genes, was 
unable to produce 5‘-FDA. From this data it would appear that 
each modification on its own is insufficient to enable 5’-FDA 
production in the cells. Apart from expression of flA1, both 
deletion of crcB and expression of samT are required for 
fluorometabolite synthesis in E. coli.  
The engineered E. coli developed here can convert fluoride 
to an organofluorine metabolite (5‘-FDA) in vivo. The only other 
fluorometabolite produced by heterologous expression of the 
fluorinase gene from S. cattleya (flA) is fluorosalinosporamide 
which was induced in the marine organism Salinospora tropica. In 
that case, flA was inserted directly into a target gene to disrupt a 
highly homologous chlorinase gene within the 
(chloro)salinosporamide gene cluster. This resulted in the 
production of the fluoroanalogue.[36] Although a notable outcome, 
the gene swap was very conservative and replaced a like-for-like 
gene in a biosynthetic cluster. Also, the engineered S. tropica was 
extremely susceptible to fluoride ion toxicity which compromised 
the ability to carry out practical biotransformations. The ability of 
this engineered E. coli to produce 5’-FDA by manipulating 
intracellular fluoride ion and SAM concentrations, offers a first 
Figure 2. 19F-NMR spectra of lysates from strains MK004 – BL21(DE3) + pflA1 
(Top-left), MK010 – ΔcrcB + pflA1 (Middle-left), MK015 – ΔcrcB + pflA1 + 
psamT (Top-right), MK019 – ΔcrcBΔdeoD + pflA1 + psamT (Middle-right). 2-
Fluoroethanol was used as an internal reference (-226.8 ppm) and 5’-FDA is 
detected at -232.5 ppm. The multiplicities arise from couplings between 19F and 
1H nuclei. Bottom-left: Zoomed 19F-NMR spectrum of the fluorometabolite 
peak. 5'-FDA reference (blue), cell lysate of strain MK015 spiked with synthetic 
5'-FDA (red, H-coupled and H-decoupled) and cell lysate of the same strain non-
spiked (green). Bottom-right: Production yields in different strains as 
measured from 2 biological replicates. The computed molarity corresponds to 
the intracellular concentration of 5’-FDA. 
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important step towards the successful engineering of 
fluorometabolites in industrial microorganisms. 
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